CVX 045

Drug Profile

CVX 045

Alternative Names: CovX 045; CVX-045; PF-4856882

Latest Information Update: 15 Apr 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CovX
  • Developer Pfizer
  • Class Antibodies; Peptides
  • Mechanism of Action Thrombospondin 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 31 Mar 2009 Discontinued - Phase-I for Solid tumours in USA (Parenteral)
  • 28 Feb 2007 Phase-I clinical trials in Solid tumours in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top